New anti-VEGF therapies seeking Aussie approval
The suppliers of two new anti-VEGF therapies recently cleared in the US that work to reduce macular disease treatment burdens ...
Tag: DME
Roche’s faricimab meets primary endpoint in DME trial
Swiss drug giant Roche is poised to pursue regulatory clearance for its new faricimab antibody for diabetic macular edema (DME) ...
Tax credit strengthens Opthea’s balance sheet; follows AU$175m IPO on US exchange
Melbourne biopharmaceutical company Opthea has received an $8.5 million research and development (R&D) tax credit from the Australian tax authority ...
Opthea becomes ASX top 300 company
Melbourne biopharmaceutical company Opthea has announced its inclusion on the ASX 300, just days after its lead drug candidate met ...
Opthea progresses DME trials despite COVID-19 disruption
Results are imminent in biopharmaceutical company Opthea’s latest clinical trial evaluating the safety and efficacy of its lead drug candidate ...
Sleep apnoea linked to diabetic macular oedema
New research has drawn a link between severe sleep apnoea and diabetic macular oedema, firming up the connection between the ...